Anavip

Last updated

Anavip
Clinical data
Trade names Anavip
Other names
  • Crotalidae immune F(ab')2 (equine)
  • Viper antivenom
Identifiers
PubChem SID
DrugBank
UNII

Anavip (stylized as ANAVIP) is the trade name of a snake antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation. [1] [2] [3] As defined by the FDA, the proper name is crotalidae immune F(ab')2 (equine). [4] It is manufactured by Instituto Bioclon for Rare Disease Therapeutics in the United States.

Anavip is a divalent fragment antigen-binding protein, F(ab')2, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus . The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')2. [5]

References

  1. ↑ Cocchio C, Johnson J, Clifton S (January 2020). "Review of North American pit viper antivenoms". American Journal of Health-System Pharmacy. 77 (3): 175–187. doi:10.1093/ajhp/zxz278. PMID   31974558.
  2. ↑ "Marketing authorization with orphan designation - USA". orpha.net. orphanet. Retrieved 19 August 2020.
  3. ↑ "Highlights of Prescribing Information". U.S. Food & Drug Administration. Archived from the original on September 29, 2019.
  4. ↑ Research Cf (2019-10-02). "ANAVIP". FDA.
  5. ↑ Laboratorios Silanes S.A. de C.V. "Highlights of Prescribing Information" (PDF). Package_Insert. Retrieved 18 August 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.